Chronic Obstructive Pulmonary Disease: Strong Product Pipeline to Influence Global Market

Published Date : Feb 16, 2016

ALBANY, New York, Feb 16, 2016: has announced the addition of a new research report offering a pipeline review for the global market for chronic obstructive pulmonary disease (COPD) market. The research study analyzes the current as well as historical performance and the growth prospects of the global COPD market.

The market report, titled, “Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying And Commercializing First-In-Class Innovation,” presents a comprehensive overview of the growth of the worldwide market for COPD, supported by the comparative reports of route of administration (RoA) and mechanism of action (MoA). It also provides crucial information on the pipeline for remedial medicines in the global COPD market on the basis of the latest updates published in news reports and press releases.

The market has also been analyzed on the basis of targeted drug in this research report. The existing COPD drug pipeline includes 212 active products. Among these, the first-in-class products segment accounts for a share of 16.5% in the overall pipeline.

This 53-page market study is prepared by sourcing data and information from the websites of the COPD market players, SEC filings, presentations by investors, press releases from market participants, and market-specific third party sources.

The report also studies all the inactive and dormant pipeline projects and provides important competitor information, assessment, and insights to conduct efficient research and design growth strategies. Further, it identifies the emerging COPD market participants with a potentially strong product portfolio and studies varied types of therapeutics under development for COPD.

For Sample Copy, click here:

This study is an attempt at estimating the size of the COPD industry at present and in the coming years. The development rate on which the COPD market will be emerging is calculated based on prevailing market dynamics. Furthermore, the research report also identifies the key market trends, the driving factors as well as the challenges and limitations the industry faces.

Moreover, several in-licensing and out-licensing strategies have been designed and developed in this report by identifying potential partners with lucrative projects to enhance and expand business prospects and scopes. It also creates remedial measures for pipeline projects by understanding the depth and center of indication of the therapeutic market for COPD.

The report also reviews the profiles of the major participants contributing to the research and development of effective treatment for chronic obstructive pulmonary diseases. According to it, GlaxoSmithKline is the leading player in the global chronic obstructive pulmonary disease therapeutics market.

This research study is aimed at assisting market participants to enhance their decision-making abilities and help them in creating efficient counter strategies in order to gain a competitive edge over peers.

To order report Call Toll Free: 866-997-4948 or send an email on